Table 1.
Correlation of histopathological factors and SFRP1 expression detected by IHC staining in patients with ampullary adenocarcinoma.
| SFRP1 expression | P | ||
|---|---|---|---|
| Low | High | ||
| No. (%) | 23 (72%) | 9 (28%) | |
| Age, years, median (range) | 66 (36–90) | 65 (32–80) | NS |
| Sex | NS | ||
| Female | 12 (75%) | 4 (25%) | |
| Male | 11 (69%) | 5 (31%) | |
| Total bilirubin, mg/dL, median (range) | 2.7 (0.5–10.8) | 2.3 (0.2–14.4) | NS |
| Direct bilirubin, mg/dL, median (range) | 1.7 (0–9.4) | 2.4 (0.1–12.4) | NS |
| CEA, units/ml, median (range) | 2.5 (0.1–21.7) | 2.0 (0.9–11.1) | NS |
| CA125, units/ml, median (range) | 13.6 (2.7–44.0) | 18.7 (8.3–66.7) | NS |
| CA199, units/ml, median (range) | 44.2 (1.4–1,860) | 137.7 (5–2,120) | NS |
| Tumor type | NS | ||
| Polypoid | 9 (64%) | 5 (46%) | |
| Infiltrative | 7 (78%) | 2 (22%) | |
| Mixed | 6 (75%) | 2 (25%) | |
| Tumor size, cm, median (range) | 3 (0.8–6.5) | 2.5 (1.0–8.0) | NS |
| Differentiation | NS | ||
| Well | 8 (67%) | 4 (33%) | |
| Moderate | 12 (80%) | 3 (20%) | |
| Poor | 2 (67%) | 1 (33%) | |
| Tumor stage | NS | ||
| T1 | 2 (67%) | 1 (33%) | |
| T2 | 5 (63%) | 3 (37%) | |
| T3 | 12 (80%) | 3 (20%) | |
| T4 | 4 (67%) | 2 (33%) | |
| Lymph node status | NS | ||
| Negative | 14 (78%) | 4 (22%) | |
| Positive | 9 (75%) | 3 (25%) | |
| Pancreatic invasion | NS | ||
| Negative | 7 (70%) | 3 (30%) | |
| Positive | 16 (76%) | 5 (24%) | |
| AJCC TNM stage | NS | ||
| Stage I | 6 (60%) | 4 (40%) | |
| Stage II | 12 (86%) | 2 (14%) | |
| Stage III | 4 (67%) | 2 (33%) | |
| Stage IV | 1 (50%) | 1 (50%) | |
SFRP1, secreted frizzled related protein 1; NS, not significant; CEA, carcinoembryonic antigen; CA125, cancer antigen 125; CA199, cancer antigen 199; AJCC TNM stage, American Joint Committee on Cancer’s tumor, node, and metastases staging system.